Physician profile

Danny S Park

Neurology (Psychiatry & Neurology) · Chicago, IL

NPI 1811148786

$18,962.56

in general payments reported to CMS, 2019-2025

47 companies · $61.21 in 2025

The $61.21 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$2,629.75
Food and Beverage$1,867.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Acorda Therapeutics, INC $10,191.62 2019-2024 Inbrija, Ampyra
Siemens Medical Solutions USA, INC. $3,076.98 2023
Biogen, INC. $646.47 2019-2025 Vumerity, Tysabri, Plegridy
Abbvie INC. $547.81 2019-2025
Ucb, INC. $539.81 2019-2024 Briviact, Rystiggo
Alexion Pharmaceuticals, INC. $435.85 2019-2024 Ultomiris, Soliris
Teva Pharmaceuticals USA, INC. $307.46 2019-2025 Austedo, Ajovy
Lilly USA, LLC $273.87 2019-2024 Emgality, Reyvow
Allergan, INC. $224.16 2019-2021
Emd Serono, INC. $220.52 2019-2023 Mavenclad
Mdd US Operations, LLC $191.38 2019-2024 Gocovri, Gocovri
Lundbeck LLC $184.30 2019-2024 Vyepti
Sunovion Pharmaceuticals INC. $164.99 2019-2022
Acadia Pharmaceuticals INC $164.72 2019-2024 Nuplazid
Amgen INC. $148.88 2020-2022
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Eisai INC. $143.52 2019-2022
Genentech USA, INC. $142.48 2019-2023 Ocrevus
Livanova USA, INC. $132.99 2019-2022
Banner Life Sciences, LLC $131.57 2021-2024
Supernus Pharmaceuticals, INC. $104.26 2019-2021
Janssen Pharmaceuticals, INC $97.87 2021-2022
Neurocrine Biosciences, INC. $93.05 2022-2024 Ingrezza, Ongentys
Astrazeneca Pharmaceuticals LP $76.14 2021-2023 Andexxa
Biohaven Pharmaceuticals, INC. $72.66 2021
Novartis Pharmaceuticals Corporation $66.26 2019-2022
Sk Life Science, INC. $48.26 2020-2021
Catalyst Pharmaceuticals, INC. $44.70 2020-2022
Kedrion Biopharma INC. $42.65 2019
Biohaven Pharmaceutical Holding Company LTD. $40.02 2022
Avanir Pharmaceuticals, INC. $39.25 2019
Si-Bone, INC. $34.69 2020
Argenx US, INC. $27.83 2023 Vyvgart Hytrulo
Abbott Laboratories $27.55 2020
Impel Pharmaceuticals INC. $27.28 2023 Trudhesa
Sumitomo Pharma America, INC. $26.02 2023 Aptiom
Pfizer INC. $24.43 2021
Avion Pharmaceuticals $22.21 2022
Akcea Therapeutics, INC. $21.35 2019
Alnylam Pharmaceuticals INC. $21.02 2023 Onpattro
Grifols USA, LLC $20.79 2023 Gamunex-C
Vertical Pharmaceuticals, LLC $19.05 2020
Adamas Pharmaceuticals, INC. $18.81 2021
Bausch Health US, LLC $17.43 2019
Xeris Pharmaceuticals, INC. $16.61 2021
Portola Pharmaceuticals, LLC $15.99 2020
Tanabe Pharma America, INC. $14.00 2019
Amneal Pharmaceuticals LLC $13.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Danny S Park

$18,962.56

in general payments reported 2019-2025

Years
2019-2025
Top company
Acorda Therapeutics, INC
Context
The $61.21 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

https://glasscript.com/doctor/173271/danny-s-park

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.